Sensenig Bethany — SEC Form 4 filings
SEC reporting owner CIK 1899935. 9 Form 4 filings on record with FilingPulse; latest filed 2026-06-11.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-02-26 to 2026-06-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 2 filings — 9,844 shares, $455,105 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 5,369 shares @ $42.25 ($226,840) in SUPERNUS PHARMACEUTICALS, INC., filed 2025-08-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Director | 6 | — | 3 legs · 9,844 sh · $455,105 | 10 |
| Alpha Cognition Inc. (ACOG) | Director | 1 | — | — | 2 |
| KalVista Pharmaceuticals, Inc. (KALV) | Director | 2 | — | — | 2 |
Form 4 filings — Sensenig Bethany
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-11 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Disposition to issuer (D): 45,000 (derivative) | EDGAR |
| 2026-04-17 | 4 | Alpha Cognition Inc. (ACOG) | Grant/award (A): 5,489 @ $0 · Grant/award (A): 6,991 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 4,475 @ $0 · Sale (S): 1,217 @ $50.31 · Sale (S): 3,258 @ $51.27 · Option exercise (M): 4,475 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 2,989 (derivative) @ $0 · Grant/award (A): 4,977 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-08-18 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Sale (S): 5,369 @ $42.25 | EDGAR |
| 2025-02-24 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 5,369 @ $0 · Disposition to issuer (D): 5,369 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 7,296 (derivative) @ $0 · Grant/award (A): 4,475 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 8,252 (derivative) @ $0 · Grant/award (A): 5,369 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1899935 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →